(Corrects typo in lead)
BASEL, Jan 30 (Reuters) - Swiss drugmaker Roche reported full-year profit on Thursday that fell short of expectations, hit by the strengthening of the Swiss franc against the U.S. dollar and the Japanese yen.
The Basel-based firm said full-year sales rose 3 percent to 46.78 billion Swiss francs ($52.22 billion), in line with analysts expectations for 46.87 billion francs in a Reuters poll. [ID:
Core earnings per share were up 6 percent at 14.27 francs, missing the average analyst forecast of 14.9 francs.
The world’s largest maker of cancer drugs guided for 2014 sales to grow in the low-to-mid single digits percentage, while core earnings per share (EPS) should grow ahead of sales.
$1 = 0.8959 Swiss francs Reporting by Caroline Copley; Editing by Maria Sheahan